We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Releases

Press Releases

Mar 29, 2021

NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer

READ PRESS RELEASE

Mar 29, 2021

NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

READ PRESS RELEASE

Mar 13, 2021

NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)

READ PRESS RELEASE

Feb 25, 2021

NLS Pharmaceutics to Participate in Upcoming Investor Conferences

READ PRESS RELEASE

Feb 2, 2021

NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering

READ PRESS RELEASE

Jan 28, 2021

NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering

READ PRESS RELEASE

Jan 21, 2021

NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy

READ PRESS RELEASE